Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...
CBCC will initially recruit for the NEO100-01 Glioblastoma (GBM) clinical trial, which is a Phase 2a study evaluating the survival impact and tolerance of intranasal NEO100, an ultra-purified perillyl ...
Plus Therapeutics' Q4 2024 earnings reveal progress with REYOBIQ nearing FDA approval & CNSide's 2025 launch. Key hires & funding bolster milestones.
A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...
ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...
Population-based cancer registries are the benchmark for assessing a country's cancer burden.1 Cancer registries across the globe play a crucial role in providing valuable data1 for monitoring ...
Pembrolizumab and XL888 in advanced CRC showed manageable safety, though limited responses and potential immunomodulatory ...
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback